Rheumatology
JAK inhibitors
"-tinib" drugs (e.g. tofacitinib, baricitinib) — Targeted oral drugs for inflammatory disease — convenient, but with specific cardiovascular and cancer cautions.
Education and reference only. This is a plain-language class overview — it deliberately contains no doses. Always check the current Summary of Product Characteristics (SmPC), the BNF and your local formulary before prescribing or administering any medicine.
Quick answer
What is JAK inhibitors?
JAK inhibitors are targeted oral drugs for moderate-to-severe inflammatory conditions such as rheumatoid arthritis, some other arthritides, inflammatory bowel disease and severe eczema, used when standard treatments are insufficient.
- How it works: They block Janus kinase (JAK) enzymes inside cells, interrupting the signalling that many inflammatory messengers use to drive disease.
- In practice: In practice JAK inhibitors are an effective oral ("targeted synthetic") option for rheumatoid arthritis and several other inflammatory conditions when conventional drugs are not enough — attractive because they are tablets rather than injections.
What it is
JAK inhibitors are targeted oral drugs for moderate-to-severe inflammatory conditions such as rheumatoid arthritis, some other arthritides, inflammatory bowel disease and severe eczema, used when standard treatments are insufficient.
How it works
They block Janus kinase (JAK) enzymes inside cells, interrupting the signalling that many inflammatory messengers use to drive disease. Damping this signalling reduces inflammation — but the same pathways are involved in immune defence and other functions, which underlies the safety cautions.
In practice
In practice JAK inhibitors are an effective oral ("targeted synthetic") option for rheumatoid arthritis and several other inflammatory conditions when conventional drugs are not enough — attractive because they are tablets rather than injections. Their use is shaped by safety signals from large studies: an increased risk, in certain higher-risk patients, of serious infections (including shingles), blood clots (venous thromboembolism), major cardiovascular events and some cancers. So they are used with particular caution — or avoided — in older patients, smokers and those with cardiovascular or clot risk factors, and prescribing follows updated regulatory advice. Before and during treatment, screening for infections (including TB and hepatitis) and monitoring of bloods, lipids and liver function are standard, and patients are counselled to report signs of infection, shingles or clot symptoms. Live vaccines are avoided; shingles vaccination is considered beforehand.
Examples
Practical use
How to take it & use it well
- Take your JAK inhibitor (such as tofacitinib, baricitinib or upadacitinib) by mouth as prescribed, usually once or twice daily, and try to take it at the same time each day.
- Before starting, you will be screened for infections such as TB and hepatitis, and you will have regular blood tests during treatment to check blood counts, lipids and liver.
- Watch for signs of infection, including shingles (a painful blistering rash), and seek advice promptly if they appear.
- Seek urgent help for symptoms of a blood clot, such as a swollen, painful leg or sudden breathlessness or chest pain.
- If you miss a dose, follow the advice for your specific medicine rather than doubling up, and do not stop suddenly without discussing it with your clinician.
Common uses
- Rheumatoid and other inflammatory arthritis
- Inflammatory bowel disease (some agents)
- Severe atopic eczema and other immune-mediated conditions
Monitoring
- Pre-treatment TB/hepatitis/infection screening
- Full blood count, lipids and liver function during treatment
- Cardiovascular and clot risk; signs of infection or shingles
Weighing it up
Advantages & disadvantages
Advantages
- Taken as tablets, they offer an oral option for rheumatoid arthritis and other inflammatory conditions, avoiding injections or infusions.
- They can control inflammation and symptoms when other treatments have not worked well enough.
- They often work relatively quickly compared with some other disease-modifying treatments.
- Once-daily options can make them convenient to fit into a routine.
Disadvantages
- They carry safety signals including serious infections (notably shingles), blood clots, major cardiovascular events and some cancers.
- They are used with extra caution in older people, smokers and those with cardiovascular risk factors.
- They require screening before starting and ongoing blood monitoring of counts, lipids and liver.
- Live vaccines must be avoided, which needs planning around treatment.
Key safety principles
What to watch for
- In higher-risk patients: increased serious infection (including shingles), blood clots, major cardiovascular events and some cancers — use with caution or avoid (older age, smokers, cardiovascular/clot risk).
- Screen for TB, hepatitis and infections before starting; avoid live vaccines (consider shingles vaccination beforehand).
- Monitor blood counts, lipids and liver function; report infection, shingles or clot symptoms.
Key interactions
What to avoid or check alongside
- Combining with other immune-suppressing medicines increases infection risk and is generally avoided.
- Some medicines that affect how the liver breaks down these drugs can raise or lower their levels, so dose adjustments may be needed.
- Live vaccines should be avoided because the suppressed immune system makes them unsafe.
- Tell your clinician about all medicines, including over-the-counter and herbal products, so interactions and clot or infection risk can be considered.
Patient & carer advice
- Report signs of infection, a painful rash (shingles), or calf/chest pain or breathlessness
- Tell us your heart, clot and smoking risk — these affect whether this drug suits you
- Avoid live vaccines and keep up your monitoring blood tests
Use with
Related clinical calculators
Dose and risk decisions for this class often depend on renal function, weight or bleeding/stroke risk. These tools help:
Answers
JAK inhibitors: frequently asked questions
Why do I need blood tests on a JAK inhibitor?
Regular tests check your blood counts, cholesterol and liver, which these medicines can affect. Monitoring helps catch problems early and keep treatment safe.
Why is shingles a particular concern?
JAK inhibitors raise the risk of shingles, a painful blistering rash from the chickenpox virus reactivating. Tell your clinician promptly if you develop such a rash.
What clot symptoms should I watch for?
Seek urgent help for a swollen, painful or red leg, or sudden breathlessness or chest pain. These medicines carry a risk of blood clots.
Can I have vaccinations while taking one?
Live vaccines should be avoided because your immune system is suppressed. Discuss any planned vaccinations with your clinician so timing can be arranged safely.
Are JAK inhibitors suitable for everyone?
They are used with extra caution in older people, smokers and those with heart or clot risk factors. Your clinician will weigh the benefits and risks for your situation.
Authoritative sources
Always verify against the source
This overview is for orientation. For doses, interactions, contra-indications and the full monograph, use:
Related guides
Medicines in this class
Common jak inhibitors by active ingredient
Individual, dose-free guides to specific medicines in this class:
Used for
Conditions this class is used to treat
See how this class fits into the wider treatment picture for each condition:
Browse by body system
Part of the bones, joints & muscles
See all the conditions, medicine classes and active-ingredient guides for this body system in one place:
Need a custom medicines or prescribing resource?
We build evidence-led clinical references, calculators and decision aids for teams.